Why peptides

Before there were drugs, there was the signal. Strip away the machinery and almost every instruction the body gives itself is a short chain of amino acids — a dozen residues, sometimes three, carrying a message between cells that have no other way to talk. Eat. Stop eating. Grow. Heal this. Sleep now. The vocabulary is tiny and the reach is enormous, and that disproportion is the single most interesting fact in the field.

Brevity is not a limitation here; it is the design. A hormone is a sentence, and a sentence that never ends stops carrying information. So the body writes short and destroys fast — most of these molecules are taken apart within minutes of being made, on purpose, so the next instruction can mean something different from the last.

For most of a century that was the end of the story: a beautiful signaling language nobody could write in. The very properties that make peptides good messengers — small, fragile, gone in minutes — make them terrible drugs. You cannot swallow one, and injecting one buys you a few minutes of effect.

Then, in the span of about fifteen years, the field learned to write. Native GLP-1 survives roughly two minutes; semaglutide carries the same message to the same receptor for about a week. That is a five-thousand-fold gap, and it was not won by making the molecule tougher — it was won by attaching it to something the body had already decided to keep. The same inversion is now producing pills where only needles worked, molecules that hit two receptors at once, and cadences stretching toward monthly.

That is a genuinely thrilling place to be standing, and it is exactly the condition under which people get sold things. A frontier is loud. The gap between what a molecule has been shown to do and what it is described as doing is widest precisely where the science is newest — and a reader arriving with a real question deserves better than to be marketed at.

So the discipline is the other half of the work, not a disclaimer bolted onto it. 73 molecules across 12 signaling families, every mechanism traced to primary literature and cited by PMID, every compound carrying a visible rigor grade from Established down to Limited so you can calibrate before you read. Where the evidence is thin, the page says thin. Where a figure comes from a rodent, it says rodent. Downgrading a claim is free here; upgrading one requires a source.

We host no storefront. One affiliate relationship is disclosed in full on the methodology page and gated on data — the sourcing note appears only where a molecule is genuinely stocked, never as a blanket pitch — because the incentive that should shape a catalog is to be correct, not to sell. And because cataloged is not the same as reachable, we publish what you can actually get as data rather than pretending the question does not exist.

So every page holds two things at once. We are bullish on the science — a signaling system this old, this economical, and this suddenly writable has earned real enthusiasm, and pretending otherwise would be its own kind of dishonesty. And we are sceptical on the page — because enthusiasm that outruns its citations is just marketing with better vocabulary.

Where the science is settled, we say so plainly. Where it is unsettled, we call it the frontier rather than a sure thing, and we tell you which one you are reading. The wonder is real. It is also earned, page by page, citation by citation.

• →Browse the catalog — every molecule, graded and cross-linked
• →Two minutes to seven days — how a disposable hormone became a weekly drug
• →Methodology & standards — how we source, grade, and bound this reference